TerminatedPHASE1, PHASE2NCT00089076

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Studying Lymphomatoid granulomatosis

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Stephen Ansell
Mayo Clinic
Intervention: ipilimumab(biological)
Enrollment: 18 enrolled
Eligibility: 18 years · All sexes
Timeline: 2004 – 2009

Study locations (1)

Mayo Clinic, Rochester, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00089076 on ClinicalTrials.gov

← Back to all trials